IMVT

Immunovant (IMVT)

About Immunovant (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in Durham, NC.

Details

Daily high

$29.85

Daily low

$27.16

Price at open

$27.32

52 Week High

$30.09

52 Week Low

$13.52

Market cap

5.9B

Dividend yield

0.00%

Volume

2.4M

Avg. volume

1.6M

P/E ratio

-10.79

Immunovant News